CD44 and triple-negative breast carcinoma: The intracytoplasmic region (ICD) of CD44 cleavage can regulate PD-L1 expression by binding to the coherence site of the PD-L1 gene’s promoter region.Therefore, CD44 is a potential target for inhibiting PD-L1 function in triple-negative breast cancer [15].